Invitrogen, a division of Life Technologies, has launched the Gibco Optmizer T-cell expansion SFM for culturing and expanding human T-cells.
According to the company, the Optmizer SFM does not require the addition of serum to achieve optimal, cost-efficient results.
The solution is intended to enable scientists to advance their research on the central role that T-cells play in human immune response.
These cells are studied by scientists conducting basic and clinical research, as well as biotechnology and pharmaceutical companies and organisations studying bio-defence.
Invitrogen formulated the Optmizer SFM to enable cell growth and viability with consistent results, without the addition of serum.
The company claims that it achieves superior performance criteria for growth, viability and cell yield under serum-free conditions.
Some products on the market for T-cell culture and expansion are limited in their performance without the addition of human serum to feed the cells - a process that adds cost, complexity and contamination risk.
The Optmizer SFM is also xeno free, meaning that it does not contain material of non-human origin, which further enhances its safety while decreasing variability of results from lot to lot.
It is currently available in research-use-only grade.
This product is manufactured under cGMP regulations and comes with an FDA drug master file to support regulatory filings.
The Optmizer SFM expands Invitrogen's portfolio of solutions for immunology research, which includes Aim V, an FDA 510(k)-cleared commercial T-cell medium for human ex-vivo tissue and cell culture processing applications, and a selection of serum- and xeno-free products.
Joydeep Goswami, vice-president of primary and stem cell systems for life technologies, said: 'This will enable an easier transition for our customers from research to clinical applications, due to fewer regulatory hurdles and processing steps in T-cell expansion, and will yield greater cost savings.'
